Precision BioSciences Strengthens Leadership for Gene Editing Innovation and Growth
- Precision BioSciences enhances leadership with Cindy Atwell and Cassie Gorsuch to drive gene editing advancements and clinical trials.
- Atwell will oversee development functions while Gorsuch focuses on non-clinical development and gene therapy discovery.
- The strengthened leadership aims to expand Precision's gene editing portfolio and foster partnerships for innovative therapies.
Precision BioSciences Enhances Leadership Team to Propel Gene Editing Advancements
Precision BioSciences, Inc., a clinical-stage gene editing company, is poised for significant growth with the recent enhancement of its senior leadership team. The appointment of Cindy Atwell as Chief Development and Business Officer brings extensive biopharma experience to the company, as she takes charge of all development functions, including clinical, regulatory, and business development. Atwell, who has been with Precision since 2019, has a proven track record in building strategic partnerships and managing program operations. Her leadership is expected to accelerate the company's in vivo gene editing program, PBGENE-HBV, which is currently progressing through Phase 1 clinical trials.
In tandem with Atwell’s appointment, Cassie Gorsuch, PhD, ascends to the role of Chief Scientific Officer, where she will oversee non-clinical development and gene therapy discovery. Gorsuch’s promotion comes as a recognition of her pivotal role in advancing the PBGENE-HBV program from its preclinical stages to clinical trials. She is tasked with generating preclinical proof of concept and IND-enabling data for further clinical studies. Additionally, Gorsuch will continue to foster relationships with external stakeholders, focusing on the company’s ARCUS gene editing technology. These leadership changes underscore Precision BioSciences' strategic intent to strengthen its position in the gene editing sector.
As Precision BioSciences transitions fully into an in vivo gene editing company, the expanded leadership team aims to enhance development capabilities and drive innovation in therapeutic applications. CEO Michael Amoroso emphasizes Atwell’s contributions to achieving regulatory milestones, which are vital for the company's growth. Together, Atwell and Gorsuch are expected to play critical roles in expanding Precision's portfolio of gene editing therapies, focusing on techniques like gene elimination, insertion, and excision. The strategic leadership enhancements reflect the company’s commitment to leveraging its proprietary ARCUS platform to address unmet medical needs through advanced gene editing solutions.
In addition to the leadership changes, Precision BioSciences’ focus on expanding its gene editing portfolio aligns with the growing demand for innovative therapies in the biopharmaceutical landscape. The company’s efforts to engage with external stakeholders will be crucial in fostering collaborative partnerships that can help expedite the development of its gene therapies.
As the field of gene editing continues to evolve, Precision BioSciences stands at the forefront, equipped with a strengthened leadership team and a clear vision to enhance its clinical offerings and deliver transformative therapies to patients.